ClinicalTrials.gg
CompletedNCT04580654Updated Oct 4, 2022

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

A Phase 1 interventional study of CSL312 in Healthy Volunteers, sponsored by CSL Behring. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This will be a 2- part, phase 1, open-label, single center, single ascending dose study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of subcutaneous (SC) and intravenous (IV) administration of CSL312 in healthy adult Japanese and Caucasian subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Caucasian and Japanese male or female subjects 18 to 55 years old (inclusive) that meet the following criteria at Screening:

    • Japanese subjects defined as being born in Japan, having not lived outside of Japan for more than 10 years, and having both parents and four grandparents who are of Japanese ancestry.
    • Caucasian subjects, defined as having both parents and four grandparents descended from and of the peoples of Europe, the Middle East, or North Africa, who are body weight-matched (± 15%) 1:1 with Japanese subjects.
  • Body weight in the range of ≥ 50 kg and ≤ 100 kg
  • of ≥ 18 kg/m2 and ≤ 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Positive serology test for (HIV)-1 / 2 antibody, virus (HBV) surface antigen (HBsAg) or virus (HCV) antibody.
  • Received any live viral or bacterial vaccinations within 8 weeks of Screening or is expected to receive any live virus or bacterial vaccinations during the study.
  • Evidence of current active infection.
  • Known or a history of malignancy in the past 5 years .
  • Blood pressure or pulse rate measurements outside the normal range for the subject's age.
  • Female subject of or fertile male subject either not using or not willing to use an acceptable method of
  • Pregnant, breastfeeding, or not willing to cease breastfeeding.
  • Donation or loss of more than 500 mL of blood within 3 months, or donated plasma within 7 days
  • History of arterial or venous thrombosis, bleeding disorder, or any abnormal coagulation test result
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    CSL312 (Cohort 1a, low dose)

    Factor XIIa antagonist monoclonal antibody administered subcutaneously

    Biological: CSL312

  • Experimental
    CSL312 (Cohort 1b, low dose)

    Factor XIIa antagonist monoclonal antibody administered subcutaneously

    Biological: CSL312

  • Experimental
    CSL312 (Cohort 2, high dose)

    Factor XIIa antagonist monoclonal antibody administered subcutaneously

    Biological: CSL312

  • Experimental
    CSL312 (Cohort 3, low dose)

    Factor XIIa antagonist monoclonal antibody administered intravenously

    Biological: CSL312

  • Experimental
    CSL312 (Cohort 4, high dose)

    Factor XIIa antagonist monoclonal antibody administered intravenously

    Biological: CSL312

Interventions

  • BiologicalCSL312

    Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

    Also known as: Factor XIIa antagonist monoclonal antibody, garadacimab

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

  2. Area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

Secondary outcomes

  1. Time to maximum concentration (Tmax) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

  2. Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

  3. Half-life (t1/2) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

  4. Apparent clearance (CL/F) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

  5. Apparent volume of distribution (Vz/F) of CSL312 after subcutaneous dosing

    Time frame: Up to 85 days postdose

  6. Cmax of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  7. Tmax of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  8. AUC0-last of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  9. AUC0-inf of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  10. t1/2 of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  11. Clearance (CL) of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  12. Volume of distribution (Vd) of CSL312 after intravenous dosing

    Time frame: Up to 85 days postdose

  13. Mean FXIIa-mediated kallikrein activity

    Time frame: Up to 85 days postdose

  14. Number of subjects experiencing adverse events (AEs)

    Time frame: Up to 85 days postdose

  15. Percentage of subjects experiencing AEs

    Time frame: Up to 85 days postdose

  16. Number of subjects experiencing serious adverse events (SAEs)

    Time frame: Up to 85 days postdose

  17. Percentage of subjects experiencing SAEs

    Time frame: Up to 85 days postdose

  18. Number of subjects experiencing adverse events of special interest (AESIs)

    Time frame: Up to 85 days postdose

  19. Percentage of subjects experiencing AESIs

    Time frame: Up to 85 days postdose

  20. Number of subjects experiencing Anti-CSL312 antibodies

    Time frame: Up to 85 days postdose

  21. Percentage of subjects experiencing Anti-CSL312 antibodies

    Time frame: Up to 85 days postdose

  22. Number of subjects with injection / infusion site reaction by severity

    Time frame: Up to 48 hours after start of infusion or injection

  23. Percentage of subjects with injection / infusion site reaction by severity

    Time frame: Up to 48 hours after start of infusion or injection

07

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in May 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2020
First posted
Oct 8, 2020
StartActual
Oct 29, 2020
Primary completionActual
May 7, 2021
CompletionActual
May 7, 2021
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04580654
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Oct 29, 2020
Primary completion
May 7, 2021
Completion
May 7, 2021
Last update
Oct 4, 2022

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion